drugset / Trial / NCT00821392

Phase III Trial of Febuxostat in Korea Gout Patients

NCT00821392

Phase 3 Completed 181 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was designed to evalute the efficacy and safety of Febuxostat after oral administration to patientd with gout in Korea

Timeline

Start
2006-08
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Febuxostat Small molecule 40 mg Oral
Comparator Febuxostat Small molecule 80 mg Oral
Comparator Febuxostat Small molecule 120 mg Oral

Indications